BRD3

Overview

BRD3 (Bromodomain-Containing Protein 3) is a member of the BET (Bromodomain and Extra-Terminal) family of epigenetic readers that recognize acetylated lysine residues on histone tails and recruit transcriptional regulatory complexes. BRD3 has been identified as a significantly mutated gene in lung adenocarcinoma, with truncating loss-of-function mutations suggesting a tumor suppressor role in this context.

Alterations observed in the corpus

  • Truncating (loss-of-function) mutations identified in lung adenocarcinoma WES study (Broad, 183 tumors); BRD3 was statistically significant by InVEx analysis PMID:22980975

Cancer types (linked)

  • LUAD: BRD3 truncating mutations identified as significantly mutated in the Broad lung adenocarcinoma WES cohort (183 tumors); significance established by InVEx functional enrichment analysis PMID:22980975

Co-occurrence and mutual exclusivity

Therapeutic relevance

  • BET bromodomain inhibitors (e.g., JQ1, I-BET762) target BRD3 and related BET family members; no direct therapeutic data in LUAD reported in the corpus.

Open questions

  • Whether BRD3 truncating mutations act as drivers or passengers in LUAD and whether they confer sensitivity to BET inhibitors remains to be determined.

Sources

  • PMID:22980975 — Lung adenocarcinoma WES (Broad Institute, 183 tumors)

This page was processed by entity-page-writer on 2026-05-06.